echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > New research confirms that MET expansion is a driving factor for some non-small cell lung cancer

    New research confirms that MET expansion is a driving factor for some non-small cell lung cancer

    • Last Update: 2021-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A study led by Dr.


    Camidge said that significant progress has been made in the treatment of non-small cell lung cancer.


    "We are beginning to realize that non-small cell lung cancer is more than just a disease," Camidge said


    Gene amplification becomes a driving factor for cancer


    This new paper titled "Crizotinib in Patients With MET-Amplified NSCLC" was published in the Journal of Thoracic Oncology and introduced the third method of defining NSCLC subgroups


    "Unlike gene mutations or gene rearrangements-either present or not-gene amplification is a constant variable," Camidge said


    In this Pfizer-sponsored study, Camidge and other researchers paid special attention to MET amplification


    Theoretically, if MET expansion is a driving factor in some patients with non-small cell lung cancer, inhibition of MET can slow or prevent disease progression in these patients


    During the study period, a total of 88 patients with different levels of MET amplification were treated with crizotinib


    The results showed that patients with the highest level of MET amplification had the highest response rate to crizotinib treatment and longer survival without tumor progression, while patients with lower levels of MET amplification had a poorer response to treatment


    Camidge said: "For this rare subtype of lung cancer, this is a long and difficult process, but I think this is a good evidence that some patients only cause cancer because of MET amplification


    Detection and treatment for MET amplification


    Camidge said there are many reasons why non-small cell lung cancer driven by MET expansion is unique


    If lung cancer occurs in young people and people who have never smoked, doctors will associate cancer with oncogenes


    Because of this, Camidge believes that patients with non-small cell lung cancer without a confirmed driver gene should consider MET amplification testing


    As for the use of MET inhibitors to treat patients with non-small cell lung cancer driven by MET expansion, Camidge said that pharmaceutical companies have begun to explore MET expansion as an additional target for new and existing MET inhibitors


    "This is a truly actionable oncogene," he said
    .
    "It's rare, but it's real
    .
    "

    ###

    Crizotinib in Patients With MET-Amplified NSCLC

    https://doi.
    org/10.
    1016/j.
    jtho.
    2021.
    02.
    010


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.